(Circulation. 1996;93:1780-1783.)
© 1996 American Heart Association, Inc.
Articles |
Insulin Resistance, Its Consequences, and Coronary Heart Disease
Must We Choose One Culprit?
From the Department of Medicine, Stanford University School of Medicine, Stanford, Calif, and Shaman Pharmaceuticals, Inc, South San Francisco, Calif.
Key Words: Editorials • insulin • atherosclerosis • coronary disease
 |
Introduction |
|---|
 Top Introduction References |
|---|
Approximately 25 years ago, our research group1 2 used quantitative methods to show that resistance to insulin-mediated glucose disposal was present in patients with either impaired glucose tolerance or NIDDM. These initial observations have been confirmed on multiple occasions since then, and there is now a large body of evidence that shows that this defect is present in the vast majority of glucose-intolerant individuals.3 4 5 6 7 8 In addition, several reports9 10 11 demonstrated that first-degree relatives of patients with NIDDM are also relatively insulin resistant compared with well-matched volunteers without a family history of NIDDM. Finally, prospective studies12 13 14 15 16 have identified insulin resistance and/or compensatory hyperinsulinemia as the initial defect in the development of NIDDM. Thus, the central role of insulin resistance in the pathogenesis and clinical course of patients with NIDDM has been well established. Of greater relevance to the IRAS study of "Insulin Sensitivity and Atherosclerosis" published in this issue of Circulation17 is recent awareness that the ability of insulin to mediate glucose disposal can differ by as much as 10-fold in subjects with normal glucose tolerance.18 19 Because the degree of insulin resistance in a substantial portion of these persons approaches that seen in patients with impaired glucose tolerance or NIDDM, it is assumed that they are able to secrete enough insulin to overcome the insulin resistance and maintain normal glucose tolerance.
Unfortunately, the philanthropic response on the part of the pancreatic
ß-cell is not without cost, and in 1988,20 it was
emphasized that these individuals were at increased risk to have higher
plasma TG and lower HDL cholesterol concentrations and
higher blood pressure. More importantly, it was suggested that the
cluster of abnormalities associated with insulin resistance, designated
as Syndrome X, significantly increased the risk of CHD. Given this
background, it should come as no surprise to the reader that we were
delighted to see the results of the IRAS investigators. Although many
publications have identified an association between various facets of
Syndrome X and CHD, this is the first report in which quantitative
methods have been applied to measure insulin action, the step we
believe to be most fundamental in the development of this syndrome.
Indeed, for this reason alone, demonstration by the IRAS investigators
that it is possible to measure insulin sensitivity in 
1400 subjects
is of great importance.
In addition to showing that there is a significant association between differences in insulin sensitivity and IMT of the internal carotid artery, the results of the IRAS also emphasize that the magnitude of the relationship is quite robust. Indeed, the conclusion of the investigators,17 consistent with their data, is that "moderate differences in insulin sensitivity were associated with differences in IMT nearly as large as those associated with many of the traditional cardiovascular risk factors." In this context, it would have been useful if the IRAS investigators had been somewhat more pathophysiological in their approach to data analysis. For example, LDL cholesterol and HDL cholesterol are similar in that both are considered to be traditional risk factors for CHD, but they are quite different in that concentrations of HDL cholesterol but not LDL cholesterol are highly correlated with insulin resistance.20 21 Consequently, it would have been interesting to have seen the impact on the relationship between insulin sensitivity and IMT if these two variables had been entered into the statistical models separately. In addition, because high TG and low HDL cholesterol concentration are both associated with insulin resistance,20 21 we find it inexplicable that TG concentration was not entered into any of the statistical models. The fact that TG concentration was not considered in the statistical analysis is an important issue, and we will return to it.
Finally, consideration of the importance of traditional risk factors in the genesis of CHD is not as easy to address as it might seem. Thus, in addition to the previously mentioned association between insulin resistance and TG and HDL cholesterol concentrations,20 21 it should be remembered that there is also a relationship between insulin resistance and hypertension.22 To this must be added the fact that smokers are more insulin resistant and dyslipidemic than nonsmokers.23 24 Consequently, even our "traditional" view of traditional risk factors for CHD may need modification to take into consideration the impact of insulin resistance on these variables.
The IRAS investigators17 stress that longitudinal studies will be necessary to further clarify the various relationships described in their report. We welcome this cautionary statement, because great care must be taken when one extrapolates from cross-sectional relationships to causality. However, we think it is important to also urge caution before we accept two very important conclusions drawn by the IRAS investigators. Our first concern, and the simplest one, relates to their statement that "this relationship of [insulin sensitivity] with atherosclerosis was not seen in black subjects." By implication, it is suggested that insulin resistance or its consequence does not play a role in the pathogenesis of CHD in blacks. We believe this is a dangerous conclusion to be drawn from a cross-sectional study conducted in several different centers, with 60% of the blacks enrolled from just one center (and none from two of the centers), and given that this was not a population-based study. Of greater concern is the fact that the baseline characteristics of the black subjects were quite different from the other two population groups; eg, they had greater values for IMT, were the most insulin resistant, weighed the most, and had a higher proportion of diabetes, and more than half the group was hypertensive. (It should be noted that blacks were more insulin resistant despite the fact that they had the lowest ratio of waist-to-hip girth.)
Although none of the issues outlined above rule out the possibility that there is an ethnic difference in the association between insulin resistance and atherogenesis in blacks compared with the two other ethnic groups studied, we are uncomfortable with this conclusion. First, the lack of a relationship between insulin sensitivity and IMT in blacks may simply be a reflection of a "plateau effect"; ie, this group was so insulin resistant, hypertensive, diabetic, and atherogenic that the relationship between variation in insulin sensitivity and IMT could no longer be discerned. In short, the untoward effects of insulin resistance had been realized already. Second, we do not find compelling the view that the similarity between the findings in Hispanics and non-Hispanic whites, as differentiated from blacks, is because the two former population groups are ethnically closer together than either group is with individuals of African descent. It is clear that the association between insulin resistance and atherosclerosis is not limited to populations of European ancestry. For example, all of the relationships between insulin resistance and its consequences, including documented CHD, have been shown to exist in individuals of Chinese ancestry.25 26 27 Furthermore, insulin resistance in Japanese patients with angiographically documented CHD has been demonstrated recently, including evidence of a significant relationship between degree of insulin resistance and severity of CHD.28 Finally, the IRAS investigators17 comment that the lack of a relationship between insulin resistance and atherosclerosis is "reminiscent of the lack of association of [insulin sensitivity] with blood pressure in blacks in some studies." The fact that a population-based study did not reveal any correlation between blood pressure and insulin resistance must be put into perspective with the observation that blacks with high blood pressure have been shown to be insulin resistant compared with normotensive members of the same ethnic group.29 Thus, although it is possible, we would be surprised if blacks, as distinct from several population groups, were unique in that insulin resistance or its consequences do not increase risk of CHD.
Of even greater concern to us is the conclusion, at least in
non-Hispanic whites and Hispanics, that "insulin resistance may have
an independent effect on atherogenesis," unrelated to any other risk
factor! Although it is always tempting to imply
pathophysiological causality from
epidemiological data, it is an enticement that is probably best
spurned. In the first place, one should consider the shortcomings of
the statistical methods used. For example, the authors17
conclude "that the relation of insulin sensitivity with
atherosclerosis is stronger than that between insulin
measures and atherosclerosis." However, this does
not rule out the possibility that the compensatory
hyperinsulinemia that is directly related to degree
of insulin resistance in nondiabetic subjects18 19 plays a
role, direct or indirect, in the pathogenesis of
atherosclerosis. The reproducibility of the method used
to quantify insulin sensitivity in this study17 has been
estimated to have a coefficient of variation of 15% when the study
is performed twice in the same person.30 In contrast, the
plasma insulin concentration 2 hours after an oral glucose tolerance
test varied by more than 30% in half of a group of normal subjects
studied 48 hours apart in a clinical research setting.31
It is obvious that the more precisely two variables are measured,
the greater the chances that a relationship between them might be
discerned. In addition, the complexity involved in the regulation of
the variable in question cannot be ignored. Thus, although the
method used to quantify insulin sensitivity is complicated, the
phenomenon measured is a straightforward one. Conversely, the
measurement of plasma insulin concentration is quite simple, but the
variable in question is a complex result of degree of insulin
resistance, plasma glucose concentration, and pancreatic insulin
secretory response,19 not to mention differences in
insulin catabolic rate. This issue is further confounded by the
variable relationship that exists between insulin resistance and
hyperinsulinemia in the three study groups. There
is an approximate 10-fold variability between degrees of insulin
resistance in normal subjects, with a strong, direct relationship
between degree of insulin resistance and extent of the plasma insulin
response.18 19 In contrast, there is much less variability
in the degree of insulin resistance in patients with
NIDDM.8 20 Indeed, it is stated by the IRAS
investigators17 that no insulin sensitivity was detected
in 15% of the population, or 210 subjects, primarily those with
NIDDM. Thus, 50% of the patients with NIDDM who were studied were
absolutely insulin resistant by the technique used.
Furthermore, the relationship between insulin resistance and plasma
insulin response to glucose can range from a positive to a negative one
in this heterogeneous population.32
Consequently, we find it necessary to question the wisdom of attempting
to glean a common relationship between insulin resistance, plasma
insulin response, and IMT given the heterogeneity of
the associations that exist within each subgroup on which the
analysis was based.
Finally, what we find most confusing in the article by the IRAS investigators17 is the exclusion of TG metabolism from their analysis of the link between insulin resistance and CHD. Perhaps the best way to approach this issue is first to focus on the relationship between insulin resistance, compensatory hyperinsulinemia, ambient FFA concentrations, hepatic VLDL-TG secretion, and plasma TG concentrations. Specifically, if an insulin-sensitive person is infused with glucose, it will lead to an increase in plasma insulin concentration, an increased rate of insulin-mediated disposal, a fall in plasma FFA and glycerol concentrations, and, in the absence of the essential substrate, a decline in hepatic VLDL-TG secretion and plasma TG concentration. This series of events does not in the least mimic patients with endogenous hyperglyceridemia, who are insulin resistant and hyperinsulinemic33 34 and have higher FFA and glycerol concentrations despite their higher insulin levels.35 Multiregression analysis of these data35 indicated that the daylong plasma TG response to conventional meals was significantly correlated with both daylong insulin and FFA responses. Patients with type I diabetes in poor glycemic control are also insulin resistant and have markedly elevated FFA concentrations.36 However, their daylong free insulin levels are not elevated, and they have normal values for hepatic VLDL-TG secretion rates and plasma TG concentrations.36 The significance of these different clinical vignettes is important for the following reasons. First, they reinforce the difficulty inherent in the attempt to differentiate the pathophysiological impact of insulin resistance from that of hyperinsulinemia; in the case of VLDL-TG metabolism, it appears that both changes are likely to be necessary. Second, the association between insulin resistance, compensatory hyperinsulinemia, and hypertriglyceridemia is by far the oldest and best-established downstream consequence of insulin resistance.33 34 35 Third, although controversy may continue as to whether or not hypertriglyceridemia is an independent risk factor for CHD,37 there is no doubt that the higher the plasma TG concentration, the smaller and denser the LDL particles,38 the greater the degree of postprandial lipemia,39 and the higher the levels of plasminogen activator inhibitor-I.40 All of these latter changes increase the risk of CHD, as acknowledged by the IRAS investigators.17 In light of this information and as alluded to previously, we cannot understand why the plasma TG concentration was not included in the statistical models used in Table 2 of the IRAS report17 to evaluate the independent risk factor status of insulin resistance.
In conclusion, we applaud the effort of the IRAS investigators to
quantify insulin action in 1400 subjects, and we believe their
demonstration of a relationship between degree of insulin resistance
and IMT is a finding of enormous importance. The sooner insulin
resistance and its consequences become accepted as "traditional"
risk factors for CHD, the better. On the other hand, we are quite
concerned, in a practical sense, that the link between insulin
resistance and CHD is presumed not to be operative in blacks, and in a
physiological sense, we find it difficult to
believe that insulin resistance by itself, and not its consequences,
leads to CHD. At this point, it might be best to simply acknowledge
that there is a relationship between insulin resistance and the cluster
of abnormalities associated with this defect and an increased risk of
CHD, without attempting to define the ultimate mechanism responsible
for the association or deciding that the relationship is not a
universal one.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Footnotes |
|---|
Reprint requests to G.M. Reaven, MD, Shaman Pharmaceuticals, Inc, 213 E Grand Ave, South San Francisco, CA 94080-4812.
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionReferences |
|---|
1. Shen S-W, Reaven GM, Farquhar JW. Comparison of impedance to insulin mediated glucose uptake in normal and diabetic subjects. J Clin Invest. 1970;49:2151-2160.
2. Ginsberg H, Kimmerling G, Olefsky JM, Reaven GM. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. J Clin Invest. 1975;55:454-461.
3. DeFronzo R, Diebert D, Hendler R, Felig P, Soman V. Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest. 1979;63:939-946.
4. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM. Receptor and post-receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest. 1981;68:957-969.
5. Rizza RA, Mandarino LJ, Gerich JE. Mechanism and significance of insulin resistance in non-insulin-dependent diabetes mellitus. Diabetes. 1981;30:990-995. [Abstract]
6. Nankervis A, Proietto J, Aitken P, Harewood M, Alford F. Differential effects of insulin therapy on hepatic and peripheral insulin sensitivity in type 2 (non–insulin-dependent) diabetes. Diabetologia. 1982;23:320-325. [Medline] [Order article via Infotrieve]
7. Reaven GM. Insulin resistance in non-insulin-dependent diabetes mellitus: does it exist and can it be measured? Am J Med. 1983;74:3-17. [Medline] [Order article via Infotrieve]
8.
Reaven GM, Chen Y-DI, Donner CC, Fraze E, Hollenbeck
CB. How insulin resistant are patients with
non–insulin-dependent diabetes mellitus? J
Clin Endocrinol Metab. 1985;61:32-36.
9.
Laws A, Stefanick ML, Reaven GM. Insulin
resistance and hypertriglyceridemia in
non-diabetic relatives of patients with noninsulin-dependent
diabetes mellitus. J Clin Endocrinol
Metab. 1989;69:343-347.
10. Ericksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337-343. [Abstract]
11. Ho LT, Chang ZY, Wang JT, Li SH, Liu YF, Chen Y-DI, Reaven GM. Insulin insensitivity in offspring of parents with type 2 diabetes mellitus. Diabet Med. 1990;7:31-34. [Medline] [Order article via Infotrieve]
12. Sicree RA, Zimmet PZ, King HOM, Coventry JS. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 yr. Diabetes. 1987;36:179-186. [Abstract]
13. Saad MF, Pettit DJ, Mott DM, Knowler WC, Nelson RG, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet. 1989;1:1356-1369. [Medline] [Order article via Infotrieve]
14. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes. 1990;39:283-288.[Abstract]
15. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
16.
Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE,
Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin
resistance and insulin secretory dysfunction as precursors of
non-insulin-dependent diabetes mellitus. N
Engl J Med. 1993;329:1988-1992.
17.
Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M,
Hamman R, Selby JV, Saad MF, Savage P, Bergman R, for the IRAS
Investigators. Insulin sensitivity and
atherosclerosis.
Circulation. 1996;93:1809-1817.
18.
Hollenbeck CB, Reaven GM. Variations in
insulin-stimulated glucose uptake in healthy individuals with
normal glucose tolerance. J Clin Endocrinol
Metab. 1987;64:1169-1173.
19. Reaven GM, Brand RJ, Chen Y-DI, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes. 1993;42:1324-1332. [Abstract]
20. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607. [Abstract]
21. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med. 1992;231:25-30. [Medline] [Order article via Infotrieve]
22. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension: parallels between human disease and rodent models. Diabetes Care. 1991;14:195-202. [Abstract]
23. Facchini FS, Hollenbeck CB, Jeppesen J, Chen Y-DI, Reaven GM. Insulin resistance and cigarette smoking. Lancet. 1992;339:1128-1130. [Medline] [Order article via Infotrieve]
24.
Eliasson B, Attvall S, Taskinen M-R, Smith U.
The insulin resistance syndrome in smokers is related to smoking
habits. Arterioscler Thromb. 1994;14:1946-1950.
25. Shen D-C, Kuo SW, Shain LR, Fuh MT, Wu DA, Chen Y-DI, Reaven GM. Insulin secretion and insulin action in Taiwanese with type 2 diabetes. Diabetes Res Clin Pract. 1988;4:289-293. [Medline] [Order article via Infotrieve]
26.
Shen D-C, Shieh S-M, Fuh M-T, Wu D-A, Chen Y-DI, Reaven
GM. Resistance to insulin-stimulated glucose uptake in
patients with hypertension. J Clin Endocrinol
Metab. 1988;66:580-583.
27. Young MH, Jeng C-Y, Sheu WH-H, Shieh S-M, Fuh MM-T, Chen Y-DI, Reaven GM. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. Am J Cardiol. 1993;72:458-460. [Medline] [Order article via Infotrieve]
28. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary heart disease documented with angiography. Diabetes Care. 1996;19:1-7. [Abstract]
29.
Falkner B, Hulman S, Kushner H.
Insulin-stimulated glucose utilization and borderline
hypertension in young black adults.
Hypertension. 1993;22:18-25.
30. Abbate SL, Fujimoto WY, Brunzell JD, Kahn SE. Effect of heparin on insulin-glucose interactions measured by the minimal model technique: implications for reproducibility using this method. Metabolism. 1993;42:353-357. [Medline] [Order article via Infotrieve]
31. Olefsky JM, Reaven GM. Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes. 1974;23:449-453. [Medline] [Order article via Infotrieve]
32. Reaven GM, Hollenbeck CB, Chen Y-DI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia. 1989;32:52-55. [Medline] [Order article via Infotrieve]
33. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest. 1967;46:1756-1767.
34. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974;57:551-560. [Medline] [Order article via Infotrieve]
35. Jeng C-Y, Fuh MM-T, Sheu WH-H, Chen Y-DI, Reaven GM. Hormone and substrate modulation of plasma triglyceride concentration in primary hypertriglyceridemia. Endocrinol Metab. 1994;1:15-21.
36. Reaven GM, Greenfield MS. Diabetic hypertriglyceridemia: evidence for three clinical syndromes. Diabetes. 1981;30(suppl 2):66-75.
37. Reaven GM. Are triglycerides important as a risk factor for coronary disease? Heart Dis Stroke. 1993;2:44-48. [Medline] [Order article via Infotrieve]
38. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest. 1993;92:141-146.
39.
Jeppesen J, Hollenbeck CB, Zhou M-Y, Coulston AM, Jones
C, Chen Y-DI, Reaven GM. Relation between insulin resistance,
hyperinsulinemia, postheparin plasma
lipoprotein lipase activity, and postprandial lipemia.
Arterioscler Thromb Vasc Biol. 1995;15:320-324.
40. Hamsten A, Winman B, Defaire U, Blomback M. Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563. [Abstract]
This article has been cited by other articles:
 |
|
 |
|
  J.-a Kim, Y. Wei, and J. R. Sowers Role of Mitochondrial Dysfunction in Insulin Resistance Circ. Res., February 29, 2008; 102(4): 401 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Qatanani and M. A. Lazar Mechanisms of obesity-associated insulin resistance: many choices on the menu Genes & Dev., June 15, 2007; 21(12): 1443 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wang, S. G. Lloyd, H. Zeng, A. Bonen, and J. C. Chatham Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2102 - H2110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yang, Y. Yang, S. Zhang, and A. M. Kahn Insulin-Stimulated Hydrogen Peroxide Increases Guanylate Cyclase Activity in Vascular Smooth Muscle Hypertension, October 1, 2003; 42(4): 569 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-A. JANSSON, F. PELLME, A. HAMMARSTEDT, M. SANDQVIST, H. BREKKE, K. CAIDAHL, M. FORSBERG, R. VOLKMANN, E. CARVALHO, T. FUNAHASHI, et al. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin FASEB J, August 1, 2003; 17(11): 1434 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zhang, Y. Yang, B. C. Kone, J. C. Allen, and A. M. Kahn Insulin-Stimulated Cyclic Guanosine Monophosphate Inhibits Vascular Smooth Muscle Cell Migration by Inhibiting Ca/Calmodulin-Dependent Protein Kinase II Circulation, March 25, 2003; 107(11): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pont, L. Duvillard, E. Florentin, P. Gambert, and B. Verges Early Kinetic Abnormalities of ApoB-Containing Lipoproteins in Insulin-Resistant Women With Abdominal Obesity Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1726 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Atkinson, S. E. Kelly, J. C. Russell, J. Bar-Tana, and G. D. Lopaschuk MEDICA 16 Inhibits Hepatic Acetyl-CoA Carboxylase and Reduces Plasma Triacylglycerol Levels in Insulin-Resistant JCR: LA-cp Rats Diabetes, May 1, 2002; 51(5): 1548 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Arcaro, A. Cretti, S. Balzano, A. Lechi, M. Muggeo, E. Bonora, and R. C. Bonadonna Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms Circulation, February 5, 2002; 105(5): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lindblad, R. D. Langer, D. L. Wingard, R. G. Thomas, and E. L. Barrett-Connor Metabolic Syndrome and Ischemic Heart Disease in Elderly Men and Women Am. J. Epidemiol., March 1, 2001; 153(5): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Olson, S. F. Kelsey, V. Bittner, S. E. Reis, N. Reichek, E. M. Handberg, C. N. Bairey Merz, and for the Women's Ischemia Syndrome Evaluation (WISE Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: A report from the NHLBI-sponsored WISE study J. Am. Coll. Cardiol., November 1, 2000; 36(5): 1565 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Sprecher and G. L. Pearce How deadly is the "deadly quartet"?: A post-CABG evaluation J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1159 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takagi, K. Yoshida, T. Akasaka, S. Kaji, T. Kawamoto, Y. Honda, A. Yamamuro, T. Hozumi, and S. Morioka Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: A serial intravascular ultrasound study J. Am. Coll. Cardiol., September 1, 2000; 36(3): 731 - 738. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Brunner, G. Wolkart, S. Pfeiffer, J. C Russell, and T. C Wascher Vascular dysfunction and myocardial contractility in the JCR:LA-corpulent rat Cardiovasc Res, July 1, 2000; 47(1): 150 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dylewicz, S. Bienkowska, L. Szczesniak, T. Rychlewski, I. Przywarska, M. Wilk, and A. Jastrzebski Beneficial Effect of Short-term Endurance Training on Glucose Metabolism During Rehabilitation After Coronary Bypass Surgery* Chest, January 1, 2000; 117(1): 47 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Kahn, J. C. Allen, C. L. Seidel, and S. Zhang Insulin Inhibits Migration of Vascular Smooth Muscle Cells With Inducible Nitric Oxide Synthase Hypertension, January 1, 2000; 35(1): 303 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. F. Wilson, W. B. Kannel, H. Silbershatz, and R. B. D'Agostino Clustering of Metabolic Factors and Coronary Heart Disease Arch Intern Med, May 24, 1999; 159(10): 1104 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. O'Donnell and W. B. Kannel Is There a Racial Predisposition to Hypertension? Hypertension, November 1, 1998; 32(5): 817 - 819. [Full Text] [PDF]
|
|
|
|
|
|
J. B. Ruige, W. J. J. Assendelft, J. M. Dekker, P. J. Kostense, R. J. Heine, and L. M. Bouter Insulin and Risk of Cardiovascular Disease : A Meta-Analysis Circulation, March 17, 1998; 97(10): 996 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gotto Jr Cholesterol Management in Theory and Practice Circulation, December 16, 1997; 96(12): 4424 - 4430. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||